Home | About | Contact

The Insider and VP - Product Sciences of Kite Pharma Inc (NASDAQ:KITE), Marc Better, Sold 9,000 Shares

Marc Better Insider Sell In a public form that was filled with the SEC, it was published that the VP - Product Sciences of Kite Pharma Inc Marc Better, an insider in bear’s eye, made a stock market sale for 9,000 shares of the public company, having a market value of $493,326 USD using an […]

News Editors : -- 4 October 2015 20:02

Marc Better Insider Sell

In a public form that was filled with the SEC, it was published that the VP - Product Sciences of Kite Pharma Inc Marc Better, an insider in bear’s eye, made a stock market sale for 9,000 shares of the public company, having a market value of $493,326 USD using an average market price per share of $54.8 USD. In the last 30 days, he also unloaded 9,000 shares with a total value of about $466,292 USD. Marc Better now indirectly owns 0 shares. He also directly owns 1888 shares. In total he holds a stake of 0.00%.

Kite Pharma Inc Sentiment and Fundamentals

It is difficult to make conclusions about Kite Pharma Inc’s future just from Marc Better’s sale because in this filing, the insider also revealed option transactions. In the form, it was reported that Marc exercised options for 9,000 shares with average price 0.3800, worth 3,420. Moreover, nine leading security analysts too forecast a cloudy future of the company with predict $-2.05 earnings-per-share and price to earnings ratio of NaN.

Just within the last 175 days, Kite Pharma Inc’s stock price have decreased by 17.98% and is in a downtrend. Our experts place SELL rating on the stock based not only because Marc’s stock sell, but also on our trend-following system which is presented on the chart below.

Institutional Ownership

As of Q2 2015, 151 institutional players have shares of Kite Pharma Inc. The tracked hedge funds have traditionally had a high interest in this company, and that was also the case in Q2 2015. The institutional ownership was 68.17% of the stock’s outstanding shares. They increased by 4.83 million the total shares they hold. As of that quarter these institutional investors owned 29.82 million shares. There were 28 funds that closed their positions and 28 that reduced them. A total of 40 funds opened new positions in Kite Pharma Inc and 66 increased their holdings.

As disclosed by SEC’s 13F filings, the firm is in Top 10 stock holdings of five institutional advisors. They are: Wildcat Capital Management Llc, Rtw Investments Llc, Ecor1 Capital Llc, Lamond Capital Partners Llc, Dsam Partners Llp.

Wildcat Capital Management Llc had the greatest investment with ownership of 2.36 million shares as of Q2 2015 for 49.28% of the fund’s portfolio. Rtw Investments Llc is another positive institutional manager possessing 400,000 shares of the company or 7.10% of their stocks portfolio. The stock is also 15.15% of the fund’s AUM. In addition Ecor1 Capital Llc have 5.72% of their stock portfolio invested in the company for 281,400 shares. The California-based fund Lamond Capital Partners Llc revealed it had acquired a stake worth 6.53% of the fund’s stock portfolio in Kite Pharma Inc. Guy Shahar’s Dsam Partners Llp is also an optimist about the company’s stock, with ownership of 342,188 shares or 3.79% of their stock portfolio.

Kite Pharma NASDAQ:KITE Company Profile

Kite Pharma, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). It is conducting a Phase II clinical trial of a TCR-based therapy and multiple Phase I-IIa clinical trials of CAR- and TCR-based therapies. The Company’s lead product candidate KTE-C19, is a CAR-based therapy, for the treatment of refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is developing a pipeline of eACT-based product candidates for the treatment of advanced solid and hematological malignancies: CD19CAR, KTE-C19CAR and EGFRvlll CAR, among others.

Company Website: Kite Pharma

This company has 72 employees. Today its market value is: $2.71 billion and it has 47.55 million shares outstanding. As of writing it has 70.00% shareholders and the institutional ownership stands at 70.00%. Kite Pharma Inc was incorporated in Delaware on 2009-06-01. The stock closed at $56.990002 yesterday and it had average 2 days volume of 192170 shares. It is down from the 30 days average shares volume of 242787. Kite Pharma Inc has a 250 days low of $28.55 and a 250 days high of $89.20. The stock price is below the 200 days simple moving average. Kite Pharma Inc last issued its quarterly earnings report on 08/10/2015. The company reported -0.48 EPS for the quarter, missing the consensus estimate of -0.41 by 0.07. The company had a revenue of 4.40 million for 6/30/2015 and 2.88 million for 3/31/2015. Therefore, the revenue was 1.52 million up.

* The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31 - 2015.

* 25% of the shares subject to the stock option vested and became exercisable on January 2 - 2014 - and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.

Related Articles
Fallow us
Real Time Web Analytics